Seoul, South Korea

Eun Bong Lee


 

Average Co-Inventor Count = 2.6

ph-index = 6

Forward Citations = 207(Granted Patents)


Location History:

  • Chungcheongnam-do, KR (2007 - 2011)
  • Seoul, KR (2011 - 2018)

Company Filing History:


Years Active: 2007-2018

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: Eun Bong Lee: Innovator in Biomedicine

Introduction

Eun Bong Lee is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of biomedicine, particularly in the development of innovative therapeutic antibodies. With a total of 10 patents to his name, Lee's work has the potential to impact the treatment of various immunological diseases.

Latest Patents

One of his latest patents is the Anti-TNF-α/CXCL10 double-targeting antibody and its use. This invention relates to a bispecific antibody that effectively binds to both tumor necrosis factor-alpha (TNF-α) and C-X-C motif chemokine 10 (CXCL10). The antibody is designed to have excellent TNF-α inhibitory activity and osteoclast differentiation inhibitory activity compared to single-targeting antibodies. This composition can be utilized in preventing or treating immunological diseases, showcasing Lee's innovative approach to addressing complex health challenges.

Career Highlights

Eun Bong Lee has worked with notable companies such as LG Electronics Inc. and Metabolic Engineering Laboratories Co., Ltd. His experience in these organizations has contributed to his expertise in the field of biomedical research and innovation.

Collaborations

Throughout his career, Lee has collaborated with esteemed colleagues, including Yeon Jin Kim and Byung Mu Huh. These partnerships have further enriched his research and development efforts.

Conclusion

Eun Bong Lee stands out as a significant figure in the realm of biomedical innovation. His contributions, particularly in the development of double-targeting antibodies, highlight his commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…